Comparable specimen collection from both ends of at-home mid-turbinate swabs

Melissa Truong^{1*}, Brian Pfau^{1*}, Evan McDermot^{1*}, Peter D. Han^{1*}, Elisabeth Brandstetter², Matthew Richardson², Ashley E. Kim², Mark J. Rieder^{1,2}, Helen Y. Chu^{1,2}, Janet A. Englund^{1,3}, Deborah A. Nickerson^{1,2}, Jay Shendure^{1,2,4}, Christina M. Lockwood^{1,2}, Eric Q. Konnick^{1,2}, and Lea M. Starita^{1,2}, *on behalf of Seattle Flu Study investigators*

1. Brotman Baty Institute For Precision Medicine, Seattle WA, USA
2. University of Washington, Seattle WA, USA
3. Seattle Children's Research Institute
4. Howard Hughes Medical Institute. Seattle WA, USA

*These authors contributed equally

Lea M Starita, PhD
University of Washington
Department of Genome Sciences
Box 355065
Seattle, WA 98195
206-685-5495
lstarita@uw.edu

Abstract

Unsupervised upper respiratory specimen collection is a key factor in the ability to massively scale SARS-CoV-2 testing. But there is concern that unsupervised specimen collection may produce inferior samples. Across two studies that included unsupervised at-home mid-turbinate specimen collection, ~1% of participants used the wrong end of the swab. We found that molecular detection of respiratory pathogens and a human biomarker were comparable between specimens collected from the handle of the swab and those collected correctly. Older participants were more likely to use the swab backwards. Our results suggest that errors made during home-collection of nasal specimens do not preclude molecular detection of pathogens and specialized swabs may be an unnecessary luxury during a pandemic.

At-home respiratory specimen collection for pathogen testing enables community sampling. Furthermore, it requires neither a healthcare worker's time nor personal protective equipment and symptomatic individuals can continue to self-isolate. However, questions remain as to whether unsupervised upper respiratory specimen collection by individuals in their homes reliably produce specimens that are of high enough quality for pathogen testing. From October 2019 through May 2020, the Seattle Flu Study (1, 2) and the greater Seattle Coronavirus Assessment Network (SCAN, scanpublichealth.org) screened 16,785 mid-turbinate swabs that were self-collected by participants at home for respiratory pathogens. The at-home kits contained a flocked, mid-turbinate swab (Copan 56380CS01 or 56750CS01) - either adult or pediatric, a tube of universal transport media (UTM), and instructions on how to self-collect a specimen or collect a specimen for a child and return it to the lab (2). Of the kits distributed to individuals in the Seattle metropolitan area, most resulted in swabs returned appropriately according to the instructions in the kit, but 138/16,785 (0.8%) kits were returned to the lab with the swab handle in the UTM tube rather than the swab itself. The swab handle is non-tapered, hard plastic with decreased surface area compared to the flocked end of the swab (**Fig 1A**). We were puzzled by this phenomenon, and sought to evaluate whether handle-collected specimens were comparable to flocked swabs themselves for molecular pathogen detection. We also assessed demographic covariates associated with errors in swab collection.

Of the 16,782 specimens, 12,006 were analyzed for the presence of 24 respiratory pathogens using our Taqman-based detection panel including the 99 specimens collected with the handle (**Table 1 and supplementary material**). Samples collected after January 1, 2020 were additionally tested for the presence of SARS-CoV-2 using a separate RT-PCR assay. As a quality control metric to determine if a sufficient nasal specimen was collected for each sample,

both assay platforms measure the amount of human RNase P. Specimens with RNase P relative cycle threshold (C_{RT}) > 28 were considered to be a failed collection. The failure rate for all properly-collected specimens was 2.0% (238/12142). We expected a high failure rate for the handle collected specimens, however only 2.9% (3/102) failed this quality control metric, a non-significant difference ($p = 0.46$, Fisher's exact test). The C_{RT} values for human marker RNase P for handle-collected specimens were higher than properly collected specimens (**Fig 1B**), with a mean C_{RT} value of 16.32 (95% CI 16.27 - 16.37) for swabs and 18.19 (95% CI 17.43 - 18.96) for handles ($p < 0.01$). However, the C_{RT} from handle-collected specimens generally fell within the same range and well below the failure threshold (**Fig 1C**), showing that the handles were indeed collecting human cells. In addition, we identified multiple respiratory pathogens, including SARS-CoV-2, at similar rates of detection with both swabs and swab handles ($p=0.52$) (**Table 1**).

We examined the clinical data associated with the samples to determine which participants were more likely to collect a specimen with the handle. Participants who swabbed with the handle were more likely to be older (**Fig 2A**), with a median age of 62 compared to 39 for those who followed the instructions ($p < 0.01$). There was no significant difference in handle use between men and women ($p=0.22$) or across income brackets (supplementary material). Interestingly, participants who had erroneously used the handle were more confident that they had collected a quality specimen (**Fig 2B**, 73% highly confident with the handle vs. 62% with the swab, $p=0.02$), and reported lower overall discomfort (**Fig 2C**, 42% reported no discomfort with the handle vs. 16% with the swab, $p<0.01$).

We investigated unanticipated operator error in two large studies employing at-home mid-turbinate swab collection, and determined that participants who used the plastic handle rather than flocked swab to collect their sample and submit it to a laboratory were able to collect an adequate nasal specimen for molecular detection of respiratory pathogens. Like other studies(3), these results suggest that the use of specialty swabs may only result in marginal increases in pathogen detection. They also suggest that even if participants do not closely adhere to instructions, they can still collect a sample that is sufficient for the molecular detection of respiratory pathogens including influenza and SARS-CoV-2. In this time of global swab shortages and an unabating pandemic, the type of swab used may not be critical for detection of SARS-CoV-2.

References:

1. Chu HY, Englund JA, Starita LM, Famulare M, Brandstetter E, Nickerson DA, Rieder MJ, Adler A, Lacombe K, Kim AE, Graham C, Logue J, Wolf CR, Heimonen J, McCulloch DJ, Han PD, Sibley TR, Lee J, Ilcisin M, Fay K, Burstein R, Martin B, Lockwood CM, Thompson M, Lutz B, Jackson M, Hughes JP, Boeckh M, Shendure J, Bedford T, Seattle Flu Study Investigators. 2020. Early Detection of Covid-19 through a Citywide Pandemic Surveillance Platform. N Engl J Med.
2. Kim AE, Brandstetter E, Graham C, Heimonen J, Osterbind A, McCulloch DJ, Han PD, Starita LM, Nickerson DA, Van de Loo MM, Mooney J, Rieder MJ, Ilcisin M, Fay KA, Lee J, Sibley TR, Bedford T, Englund JA, Boeckh M, Chu HY. 2020. Seattle Flu Study - Swab and Send: Study Protocol for At-Home Surveillance Methods to Estimate the Burden of Respiratory Pathogens on a City-Wide Scale. medrxiv;2020.03.04.20031211v1. Infectious

Diseases (except HIV/AIDS). medRxiv.

3. Tu Y-P, Jennings R, Hart B, Cangelosi G, Wood R, Wehber K, Verma P, Vojta D, Berke EM. 2020. Patient-collected tongue, nasal, and mid-turbinate swabs for SARS-CoV-2 yield equivalent sensitivity to health care worker collected nasopharyngeal swabs.
medrxiv;2020.04.01.20050005v1. Infectious Diseases (except HIV/AIDS). medRxiv.

Acknowledgements: We would like to thank the Seattle Flu Study and SCAN participants for their invaluable contributions to this research, the entire Seattle Flu Study team for making this study possible and Katrina Van Raay for R code.

The Seattle Flu Study and SCAN are administered by the Brotman Baty Institute for Precision Medicine and funded by Gates Ventures, the private office of Bill Gates. The funder was not involved in the design of the study and does not have any ownership over the management and conduct of the study, the data, or the rights to publish. LMS and JS are funded by 1RM1HG010461-01 from the NHGRI and JS is an Investigator of the Howard Hughes Medical Institute. REDCap at ITHS is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1 TR002319.

Ethics Approval: The Seattle Flu Study received approval by the University of Washington's Institutional Review Board at the (UW IRB; STUDY00006181) and informed consent was obtained prior to study enrollment. Participants participated in SCAN as part of public health surveillance.

Competing interests: Helen Chu is a consultant for Merck and GlaxoSmithKline, and receives research funding from Ellume, Cepheid and Sanofi-Pasteur. Jay Shendure is a consultant with Guardant Health, Maze Therapeutics, Camp4 Therapeutics, Nanostring, Phase Genomics, Adaptive Biotechnologies, and Stratos Genomics, and has a research collaboration with Illumina. Janet Englund is a consultant with Sanofi Pasteur and Meissa Vaccines.

Seattle Flu Study Investigators Principal Investigators: Helen Y. Chu^{1,7}, Michael Boeckh^{1,2,7}, Jeffrey S. Duchin¹⁰, Janet A. Englund^{3,7}, Michael Famulare⁴, Barry R. Lutz^{5,7}, Deborah A. Nickerson^{6,7}, Mark J. Rieder⁷, Lea M. Starita^{6,7}, Matthew Thompson⁹, Jay Shendure^{6,7,8}, and Trevor Bedford^{2,6,7}

Affiliations:

1 Department of Medicine, University of Washington

- 2 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center
- 3 Seattle Children's Research Institute
- 4 Institute for Disease Modeling
- 5 Department of Bioengineering, University of Washington
- 6 Department of Genome Sciences, University of Washington
- 7 Brotman Baty Institute For Precision Medicine
- 8 Howard Hughes Medical Institute
- 9 Department of Family Medicine, University of Washington
- 10 Public Health – Seattle King County

Figure 1. RNase P levels from either end of mid-turbinate swabs

A. Mid-turbinate swab (Copan 56380CS01), underlined handle or swab was placed in UTM by participants. **B.** C_{RT} values from all samples with RNase P detected, dashed line indicates detection limit. **C.** C_{RT} values for human RNase P among batches of specimens (arranged on the x-axis by date) where at least one handle specimen was used.

Table 1. Detection rates of respiratory pathogens

<u>Pathogen</u>	<u>Handle Present</u>	<u>Swab Present</u>
Adenovirus	1 (1.0%)	77 (0.6%)
Bocavirus	0 (0.0%)	12 (0.1%)
Enterovirus	1 (1.0%)	29 (0.2%)
Influenza A	4 (4.0%)	394 (3.3%)
Influenza B	0 (0.0%)	250 (2.1%)
Influenza C	0 (0.0%)	0 (0.0%)
Metapneumovirus	0 (0.0%)	77 (0.6%)
Parainfluenza	1 (1.0%)	50 (0.4%)
Parechovirus	0 (0.0%)	0 (0.0%)
Respiratory Syncytial Virus	2 (2.0%)	116 (1.0%)
Rhinovirus	6 (6.1%)	620 (5.2%)
SARS-CoV-2*	1 (1.1%)	119 (1.1%)
Seasonal Coronavirus	3 (3.0%)	350 (2.9%)
<i>C. pneumoniae</i>	0 (0.0%)	8 (0.1%)
<i>M. pneumoniae</i>	0 (0.0%)	28 (0.2%)
<i>S. pneumoniae</i>	3 (3.0%)	275 (2.3%)

Figure 2. Specimen collection error by age and self reported confidence and discomfort

A. Age of participants, **B.** Self reported confidence in specimen collection and **C.**

Self-reported discomfort during specimen collection by which end of the swab was used.

Appendix

Study description: The Seattle Flu Study Swab & Send program was IRB approved (STUDY00006181) and consent is obtained from participants or their guardians online at time of enrollment. The greater Seattle Coronavirus Assessment Network (SCAN) is a public health initiative under the direction of Public Health Seattle King County and permission is obtained from participants for molecular testing. For both studies, participants were sent a self-test kit to their home following online enrollment and answering a brief questionnaire. Participants collected their own mid-turbinate specimen, unsupervised, with written and video instructions (scanpublichealth.org). Instructions and materials were included for the participants to package and ship the sample according to IATA bio-specimen regulations. An in-depth description of the Seattle Flu Study Swab & Send program can be found (2). SCAN is based on the Swab & Send program with improvements aimed at achieving greater geographic and demographic diversity.

Molecular testing: Specimens were shipped to the Brotman Baty Institute for Precision Medicine via commercial couriers or the US Postal Service at ambient temperatures and opened in a class II biological safety cabinet in a biosafety level-2 laboratory. When opening specimen packages and transferring samples, technicians recorded basic information, including participant compliance with labelling and packaging instructions. Sample entries with notes indicating that mistakes had been made by participants were manually curated to determine if they belonged in the handle or the standard swab cohort. Samples with both the swab and the handle in the UTM vial were excluded from both groups.

Two or three 650 µL aliquots of UTM were collected from each specimen and stored at 4°C until the time of nucleic acid extraction, performed with the MagnaPure 96 small volume total nucleic acids kit (Roche).

Molecular assays were performed at the Northwest Genomics Center (Department of Genome Sciences, the University of Washington). Extracted nucleic acids were tested for the presence of 24 respiratory pathogens by TaqMan RT-PCR on the OpenArray platform (**Appendix Table 1**) and separate RT-PCR assay for SARS-CoV-2. For the Open Array pathogen panel, the extracted nucleic acid samples were added to a PreAmp reaction master mix containing TaqPath 1-Step RT-qPCR Master Mix CG, a custom TaqMan PreAmp oligonucleotide pool, and a spike-in control (TaqMan Universal Xeno RT control, ThermoFisher). The pre-amplification reactions were reverse transcribed and amplified for 14 PCR cycles according to the manufacturer's recommendations. The preamplified samples were diluted and added to Open Array Mastermix (ThermoFisher); the mix was then re-arrayed onto custom Open Array plates containing each RT-PCR assay in duplicate. RT-PCR was performed on a QuantStudio 12 (Applied Biosystems), with cycling parameters set according to the manufacturer's recommendations, for a total of 35 cycles. Positive and negative template controls were included in each extraction and PCR batch.

Table 1

Organism	Open Array Probe sets
Adenovirus	AdV_1of2, AdV_2of2
Seasonal Coronavirus	CoV_HKU1_CoV_NL63, CoV_229E_CoV_OC43
Influenza	Flu_A_H1, Flu_A_H3, Flu_A_pan, Flu_B_pan, Flu_C_pan
Respiratory Syncytial Virus	RSVA, RSVB

Parainfluenza virus	hPIV1_hPIV2, hPIV3_hPIV4
Metapneumovirus	hMPV
Enterovirus	EV_pan, EV_D68
Parechovirus	HPeV
Bocavirus	HBoV
Rhinovirus	RV_1of2, RV_2of2
Pneumoniae	S.pneumoniae, C.pneumoniae, M.pneumoniae

Data files from the Open Array were imported into and processed through our in-house LIMS system. Detection of each technical replicate is calculated independently using threshold values provided by ThermoFisher; the relative cycle threshold (C_{RT}) must be less than or equal to the C_{RT} threshold for each respiratory pathogen to be deemed present. Additionally, both the C_Q Conf and Amp Score must be greater than or equal to separate thresholds for a respiratory pathogen to be flagged as detected. Samples with an RNase P $C_{RT} > 28$ are considered failed. The failure rate for all properly-collected specimens versus handle-collected specimens was analyzed via R Studio (Version 1.2.5033) using Fisher's exact test.

SARS-CoV-2 was detected using a laboratory-developed test (LDT) or research assay. For the LDT, SARS-CoV-2 detection was performed using real-time RT-PCR with a probe sets targeting Orf1b and S with FAM fluor (Life Technologies 4332079 assays # APGZJKF and APXGVC4APX) multiplexed with an RNaseP probe set with VIC or HEX fluor (Life Technologies A30064 or IDT custom) each in duplicate on a QuantStudio 6 instrument (Applied Biosystems). The research assay employs only the Orf1b and RNaseP multiplexed RT-PCR in duplicate. Three or four replicates for RNase P and SARS-CoV-2 were required to have a cycle threshold

$(C_T) < 40$ for a sample to be considered positive in the LDT or both replicates must be positive in the research assay. Specimens with two replicates with SARS-CoV-2 detected are considered inconclusive.

Data Analysis: RNase P C_T values and participant demographics were analyzed in RStudio Version 1.2.5042. Replicate C_T values for RNase P were averaged, and the mean C_T values for handles and swabs were compared using a two-tailed Welch's two-sample t-test. Pathogen detection rates were compared using a paired t-test.

Participant data were collected and managed using REDCap electronic data capture tools hosted at the University of Washington (4, 5). REDCap (Research Electronic Data Capture) is a secure, web-based software platform designed to support data capture for research studies, providing 1) an intuitive interface for validated data capture; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for data integration and interoperability with external sources. Participants measured their level of discomfort and confidence in their swab technique on a voluntary online survey taken at time of sample collection. The three levels of comfort and confidence, respectively, were each compared using a Fisher's exact test. Participant age was compared using a two-tailed Welch's two-sample t-test, and sex was compared with a Pearson's Chi-squared test with Yates' continuity correction.

References:

4. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN, REDCap Consortium. 2019. The REDCap consortium:

Building an international community of software platform partners. J Biomed Inform
95:103208.

5. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG, Others. 2009. A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377–381.